Proteomics International Laboratories Ltd. Corporate Update
Proteomics International Laboratories Ltd. (PIQ.AX) closed its most recent trading session with no change in price, remaining flat at 0 % during the 24‑hour period that ended at 11:40 PM Central Europe on Friday, 23 November 2026. The share price is currently quoted at approximately AUD 0.12 on major Australian exchanges.
The company’s market capitalization stands at AUD 12.9 million, based on a total share supply of 165.4 million. In the last 24 hours, a volume of roughly AUD 6.7 k of shares was traded. Since the close of the previous month, the share price has remained unchanged. The 200‑day simple moving average is AUD 0.24. The all‑time high for the last 52 weeks was AUD 0.86 (recorded 14 January 2026), and the 52‑week low was AUD 0.10 (recorded 26 June 2026).
Upcoming Annual General Meeting
The company will hold its annual general meeting (AGM) on 20 November 2026. Shareholders will consider a series of resolutions concerning:
- Financial Reporting – presentation and discussion of the audited financial statements for the year ended 30 June 2026.
- Remuneration – adoption of a non‑binding remuneration report, including approval of incentive securities for Chief Executive Officer David Morris (director shares in lieu of short‑term cash, sign‑on rights, and long‑term performance rights).
- Directorship – re‑election of two non‑executive directors.
The AGM will provide shareholders with an opportunity to review the company’s financial position, governance arrangements, and the proposed remuneration package for the executive team before deciding on the resolutions.
Market Activity of Related Stocks
| Ticker | 24‑Hour Movement | Current Price | Market Cap (AUD m) |
|---|---|---|---|
| AZI.AX (Altamin) | +3.7 % | 0.03 | 15.1 |
| CVB.AX (Curvebeam Ai) | +5 % | 0.02 | 15.4 |
| AAU.AX (Antilles Gold) | 0 % | 0.01 | 15.3 |
| 3DP.AX (Pointerra) | +3.7 % | 0.03 | 14.9 |
| RNV.AX (Renerve) | 0 % | 0.09 | 15.1 |
Pointerra (3DP.AX) Highlights
- Reported a net loss for the year ended 30 June 2026, driven by exploration and evaluation expenses and a decline in financial asset values.
- Maintained healthy liquidity with modest cash reserve reductions.
- Continued focus on the Lake Rebecca Gold Project and the Ravensthorpe Lithium Project.
- CEO resignation; new senior geologist appointed.
- No dividends declared; conservative remuneration framework for directors and key executives.
Renerve (RNV.AX) Highlights
- Progress on flagship intranasal therapies, including a completed pivotal study for erectile dysfunction treatment.
- Commercial activity underway in the United States via telehealth and pharmacy partners.
- Advanced oesophageal motility disorder program with ethics approval and early‑stage clinical work.
- Solid cash position, zero debt, enabling support for regulatory submissions and market entry in the coming year.
About Proteomics International Laboratories Ltd.
Proteomics International Laboratories Ltd. is a biological research and drug discovery company headquartered in Australia. The company offers a range of services, including analytical and diagnostic testing, therapeutic solutions, specialist contract research, and consultancy. Its core focus areas include peptide drug discovery from venoms, disease biomarkers, and personalized medicine. Further information is available on the company’s website at www.proteomics.com.au . The company is listed on the ASX All Markets stock exchange.
